Pembolizumab Does Not Prolong Overall Survival Over Chemotherapy in an Asia-Pacific Subpopulation of Patients Previously Treated for Metastatic TNBC
Data from the subgroup of patients from Asia-Pacific with pretreated triple negative breast cancer were similar to that observed in overall KEYNOTE-119 study population